MOR - Incyte and MorphoSys presents new three-year data for blood cancer therapy

According to new three-year follow-up data disclosed by Incyte ([[INCY]] +0.6%) and MorphoSys US ([[MOR]] +6.2%), tafasitamab (Monjuvi) and lenalidomide combination has improved patient outcomes in a Phase 2 trial for relapsed or refractory diffuse large B-cell lymphoma ((DLBCL)).The single arm, open-label L-MIND study had enrolled 81 patients with a  total of 80 patients becoming evaluable for efficacy analysis as of October 30, 2020, data cut-off.The overall response rate ((ORR)) for the combination therapy reached 57.5% (95% CI = 45.9, 68.5; 46 out of 80 patients) while complete response ((CR)) rate stood at 40% (32 out of 80 patients).The median duration of response ((DoR)): 43.9 months (95% CI = 26.1, Not Reached [NR]), median overall survival ((OS)): 33.5 months (95% CI = 18.3, NR), median progression free survival ((PFS)): 11.6 months (95% CI = 6.3, 45.7).The data will be included in a poster presentation at 2021 American Society of Clinical

For further details see:

Incyte and MorphoSys presents new three-year data for blood cancer therapy